Division of Laboratory Corp. of America Holdings
Latest From Covance Inc.
Non-alcoholic steatohepatitis (NASH) was a focal point of EASL’s conference. Madrigal becomes the fifth company into Phase III in NASH, but Viking’s competing THR agonist is progressing also.
French company expects Phase III data later in 2019 that will demonstrate elafibranor’s ability to resolve NASH without worsening of fibrosis. Genfit also is partnered with Covance on a potential diagnostic test for NASH.
Sanofi and Regeneron terminate the immuno-oncology partnership signed in 2015, but will continue to collaborate on Libtayo. Biogen signs a pair of partnerships in CNS disorders, with C4 and Skyhawk, and more deals from the first day of the J.P. Morgan conference.
ICON’s CEO Steve Cutler talks candidly about the impact of biotech funding, disruptive tech providers, and the constant pressure of running one of the industry’s largest CROs.
- Contract Research, Toxicology Testing-CRO
- In Vitro Diagnostics
- Laboratory Testing Services
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Laboratory Corp. of America Holdings
- Senior Management
- John Ratliff, CEO
- Contact Info
Phone: (609) 452-4440
210 Carnegie Center
Princeton, NJ 08540-6233
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.